Gedatolisib NDA submission to FDA in HR+/HER2-/PIK3CA Wild-Type Advanced Breast Cancer completed November 24, 2025
Artios Announces Oversubscribed $115 Million Series D Financing to Accelerate Clinical Programs in Indications of High Unmet Need November 24, 2025
FAILED TRIAL: Ph 3 ASCENT-07 study of Trodelvy® (sacituzumab govitecan-hziy) vs chemo in 1L HR+/HER2-neg metastatic breast cancer patients did not meet the primary endpoint of PFS November 10, 2025
Iambic Announces Research Collaboration with Jazz Pharmaceuticals for IAM1363 and Zanidatamab Combination Cohort in HER2-Positive Breast Cancer October 29, 2025
Galera Therapeutics Announces Acquisition of Dismutase Mimetics Portfolio by Toronto-based Biossil for up to $105 Million October 29, 2025
PROs from VERITAC-2 Trial Support Clinical Benefit of Vepdegestrant in Patients with ESR1-Mutated, ER+/HER2- Advanced or Metastatic Breast Cancer Previously Treated with Endocrine-Based Therapy October 29, 2025
Independent DSMB recommends continuation of pivotal Ph 3 study of Bria-IMT™ + immune CPI in metastatic breast cancer October 25, 2025
VeraMorph Awarded an SBIR Fast Track Grant by NCI Towards Commercialization of the First Effective Oral Fulvestrant Therapy for ER+ Metastatic Breast Cancer October 21, 2025
NMPA approves trastuzumab botidotin (A166) for patients with unresectable or metastatic HER2-positive breast cancer who have received one or more prior anti-HER2 therapy October 18, 2025
Kazia Therapeutics Announces Collaboration and In-Licensing Agreement with QIMR Berghofer for a first-in-class PD-L1 degrader program October 16, 2025
TUKYSA Combination Significantly Improves PFS as First-Line Maintenance in HER2+ Metastatic Breast Cancer in HER2CLIMB-05 Trial October 16, 2025
Datroway demonstrated statistically significant OS & PFS improvement in 1L metastatic IO-ineligible TNBC patients in TROPION-Breast02 trial October 8, 2025
Supplemental BLA for Adjuvant ENHERTU Followed by THP Accepted in the US for Patients with High-Risk HER2 Positive Early-Stage Breast Cancer October 8, 2025
86% Reduction in Tumor Burden Announced in Expanded-Access Case of Metastatic TNBC Patient Treated with Paxalisib-Immunotherapy Regimen October 7, 2025
Cellectar and Evestia Clinical Announce Partnership to Support Auger-Emitting Radiopharmaceutical Clinical Trial in TNBC September 30, 2025
Enhertu demonstrated statistically significant improvement in invasive DFS vs. T-DM1 in DESTINY-Breast05 Ph III trial in patients with high-risk early breast cancer following neoadjuvant therapy September 30, 2025
Enhertu + pertuzumab granted Priority Review in the US as 1L treatment for patients with HER2-positive metastatic breast cancer September 30, 2025
FDA approves Inluriyo (imlunestrant) for adults with ER+, HER2-, ESR1-mutated advanced or metastatic breast cancer September 30, 2025
Avenzo Therapeutics Announces $60 Million Series B Financing to support pipeline advancement of oncology drug candidates September 23, 2025
